Pharsight

Drugs that contain Eravacycline Dihydrochloride

1. Xerava patents expiration

XERAVA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10961190 TETRAPHASE PHARMS Crystalline forms of eravacycline
Oct, 2037

(13 years from now)

US11578044 TETRAPHASE PHARMS Crystalline forms of eravacycline
Oct, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796245 TETRAPHASE PHARMS C7-fluoro substituted tetracycline compounds
Aug, 2029

(5 years from now)

US8906887 TETRAPHASE PHARMS C7-fluoro substituted tetracycline compounds
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 27, 2023
Generating Antibiotic Incentives Now (GAIN) Aug 27, 2028

NCE-1 date: 2027-08-28

Market Authorisation Date: 27 August, 2018

Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

XERAVA family patents

Family Patents